GRNA — Greenlight Biosciences Holdings PBC Share Price
0.000.00%
Last trade - 00:00HealthcareSpeculativeMicro Cap
- $45.43m
- $37.72m
- $6.78m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.07 | ||
| Price to Tang. Book | 2.07 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 4.39 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -188.4% | ||
| Return on Equity | -366.87% | ||
| Operating Margin | -1502.77% | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | 3 | 1.75 | 1.59 | 6.78 | 7.1 | 22.43 | 31.22% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
GreenLight Biosciences Holdings, PBC is a pre-commercial stage biotechnology company. The Company has a cell-free ribonucleic acid (RNA) production platform for the discovery, development, and commercialization of products to promote healthier plants, foods, and people. The Company's cell-free biomanufacturing platform enables the making of complex biological molecules-nucleic acids, peptides, carbohydrates, and many others using fermentation. Its technology platform provides integrated discovery, design, and development of RNA-based products used in advanced pharma discovery to agriculture and human health. It has developed two manufacturing processes, one for plant health (dsRNA) and one for human health (mRNA) that both rely on synthesis of RNA from RNA building blocks, enzymes, and deoxyribonucleic acid (DNA) templates. The Company's plant program includes the Colorado Potato Beetle Program-Calantha; Varroa Mite Program, and Powdery Mildew Complex.
Directors
- Last Annual
- December 31st, 2022
- Last Interim
- March 31st, 2023
- Incorporated
- July 2nd, 2020
- Public Since
- January 1st, 1970
- No. of Shareholders
- 131
- No. of Employees
- 262
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 151,681,314
- Address
- 29 Hartwell Avenue, LEXINGTON, 02421
- Web
- https://greenlightbiosciences.com/
- Phone
- +1 6176168188
- Auditors
- Deloitte & Touche LLP
Upcoming Events for GRNA
Q3 2023 Greenlight Biosciences Holdings PBC Earnings Release
Similar to GRNA
89bio
NASDAQ Global Market
AcelRx Pharmaceuticals
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
Adagene
NASDAQ Global Market
FAQ
What is the Greenlight Biosciences Holdings PBC share price?
As of Today at 01:10 UTC, shares in Greenlight Biosciences Holdings PBC are trading at $0.30. This share price information is delayed by 15 minutes.
How has the Greenlight Biosciences Holdings PBC share price performed this year?
Shares in Greenlight Biosciences Holdings PBC last closed at $0.30 and the price had moved by -86.57% over the past 365 days. In terms of relative price strength the Greenlight Biosciences Holdings PBC share price has underperformed the S&P500 Index by -88.47% over the past year.
What are the analyst and broker recommendations for Greenlight Biosciences Holdings PBC?
The overall consensus recommendation for Greenlight Biosciences Holdings PBC is Hold. You can view the full broker recommendation list by unlocking its StockReport.
What is the Greenlight Biosciences Holdings PBC dividend yield?
Greenlight Biosciences Holdings PBC does not currently pay a dividend.
Does Greenlight Biosciences Holdings PBC pay a dividend?
Greenlight Biosciences Holdings PBC does not currently pay a dividend.
When does Greenlight Biosciences Holdings PBC next pay dividends?
Greenlight Biosciences Holdings PBC does not currently pay a dividend.
How do I buy Greenlight Biosciences Holdings PBC shares?
To buy shares in Greenlight Biosciences Holdings PBC you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Greenlight Biosciences Holdings PBC?
As of the previous close price of $0.30, shares in Greenlight Biosciences Holdings PBC had a market capitalisation of $45.43m.
Where are Greenlight Biosciences Holdings PBC shares listed?
Here are the trading details for Greenlight Biosciences Holdings PBC:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: GRNA
What kind of share is Greenlight Biosciences Holdings PBC?
Based on an overall assessment of its quality, value and momentum Greenlight Biosciences Holdings PBC is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Greenlight Biosciences Holdings PBC share price forecast for 2023?
The analyst consensus target price for shares in Greenlight Biosciences Holdings PBC is $0.60. That is 100.33% above the last closing price of $0.30.
Analysts covering Greenlight Biosciences Holdings PBC currently have a consensus Earnings Per Share (EPS) forecast of -$1.03 for the next financial year.
What is the trend in the Greenlight Biosciences Holdings PBC share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Greenlight Biosciences Holdings PBC. Over the past six months, its share price has underperformed the S&P500 Index by -75.73%.
As of the last closing price of $0.30, shares in Greenlight Biosciences Holdings PBC were trading -64.92% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Greenlight Biosciences Holdings PBC PE Ratio?
The Greenlight Biosciences Holdings PBC PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.30.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Greenlight Biosciences Holdings PBC?
We do not have data on Greenlight Biosciences Holdings PBC's directors